Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk

Executive Summary

Agency awards $22m to support 15 clinical trials and approximately $10m for six natural history studies in rare diseases. FDA Commissioner Gottlieb highlights the program as a way for the agency to help de-risk clinical development.

Advertisement

Related Content

Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099624

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel